The Future of Personalised Cancer Medicine in Europe
Personalised medicine has the potential to change the landscape of research, treatment and care for oncology. But how can maximum benefit be best derived for patients while ensuring the highest standards of care?
The onco community agrees that the required expertise, infrastructures and networks should be established without delay to deliver tailored treatment to individual patients. And a multidisciplinary approach to diagnostics and personalised treatment according to tumour stage and location is of great importance in the quest for a cure. But what about achieving this in a cost-effective and equitable manner? What is the best pathway to take to move from concept to clinical practice? What are the regulatory challenges involved and how can we tackle them? What, in fact, is the future of personalised cancer medicine?
Dozens of different answers could be offered to these questions because of the vast array of disciplines, professions and interests involved in the research, diagnosis, treatment and care of cancer. Cancer is not a single disease, but a collection of conditions, each with different prognoses and responses to treatment. So how does personalised medicine fit into all this?
This year’s Oncopolicy Forum, an initiative of ECCO, the European CanCer Organisation, on 11 October at the Bibliothèque Solvay, in Brussels, Belgium is a much-demanded opportunity for both the oncology and policy communities to work together to tackle such burning questions. It will also enable both communities to leverage opportunities by enhancing knowledge about scientific and clinical advances in the field of personalised medicine.
The goal is to achieve a common understanding of how to move forward, and the answers developed to such questions will help shape the EU political landscape and identify strategies to ensure Europe leads the way in the fight against cancer. Free registration for the Oncopolicy Forum will open in September. Limited places will be available.